NOS2 and breast carcinoma: Since compounds 2–8 and 13–20 bear azole moieties potentially able to inhibit the iNOS16 and considering the involvement of this enzyme in breast cancer progression20, we evaluated them as iNOS inhibitors, with the aim to ascertain their potential dual-action.